Concordia denies UK liothyronine charges
Executive Summary
Concordia did not abuse its dominant position on liothyronine tablets to overcharge the UK’s National Health Service (NHS), the Canadian company has insisted in response to accusations from the country’s Competition and Markets Authority (CMA).
You may also be interested in...
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
FDA Seeks Feedback On Continuous Manufacturing
A draft ICH guidance on continuous manufacturing has been opened up for comment by the FDA, as continuous manufacturing becomes an increasingly prominent topic for the generics industry.